Abiraterone acetate: Additional Phase II data

Additional data from the U.S. and U.K. Phase II, COU-AA-003 study in 31 evaluable patients who failed doxcetaxel-based chemotherapy showed that 15 patients (48%) had a PSA decline of >50% and 6 (19%) ...